Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
The last decades have seen a major gain in understanding the action of cannabinoids and the endocannabinoid system in reward processing and the development of addictive behavior. Cannabis-derived psychoactive compounds such as Δ9-tetrahydrocannabinol and synthetic cannabinoids directly interact with the reward system and thereby have addictive properties. Cannabinoids induce their reinforcing properties by an increase in tonic dopamine levels through a cannabinoid type 1 (CB1) receptor–dependent mechanism within the ventral tegmental area. Cues that are conditioned to cannabis smoking can induce drug-seeking responses (ie, craving) by eliciting phasic dopamine events. A dopamine-independent mechanism involved in drug-seeking responses involves an endocannabinoid/glutamate interaction within the corticostriatal part of the reward system. In conclusion, pharmacological blockade of endocannabinoid signaling should lead to a reduction in drug craving and subsequently should reduce relapse behavior in addicted individuals. Indeed, there is increasing preclinical evidence that targeting the endocannabinoid system reduces craving and relapse, and allosteric modulators at CB1 receptors and fatty acid amide hydrolase inhibitors are in clinical development for cannabis use disorder. Cannabidiol, which mainly acts on CB1 and CB2 receptors, is currently being tested in patients with alcohol use disorder and opioid use disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The EC system contributes to the reinforcing effects of all three substances, and undergoes changes following adolescent exposure to them [255].”
From Consequences of adolescent drug use (2023) · cites this paper as [255]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Crystal structures of agonist-bound human cannabinoid receptor CB1
Hua, T., Vemuri, K., Nikas, S. P., Laprairie, R. B., Wu, Y., Qu, L., Pu, M., Korde, A., Jiang, S., Ho, J.-H., et al. (2017) · Nature · doi:10.1038/nature23272 · Cited by 479
RetractedMolecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,605
Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13250 · Cited by 1,039
Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.
Spanagel, R., Herz, A., & Shippenberg, T. S. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.6.2046 · Cited by 1,014
Self-citationElSohly, M. A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S., & Church, J. C. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.01.004 · Cited by 995
The dopamine hypothesis of reward: past and current status
Spanagel, R., & Weiss, F. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01447-2 · Cited by 973
Self-citationLopez-Quintero, C., Cobos, J. P. D. L., Hasin, D. S., Okuda, M., Wang, S., Grant, B. F., & Blanco, C. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.11.004 · Cited by 704
Crystal Structure of the Human Cannabinoid Receptor CB1
Hua, T., Vemuri, K., Pu, M., Qu, L., Han, G. W., Wu, Y., Zhao, S., Shui, W., Li, S., Korde, A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.10.004 · Cited by 673
‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs?
Auwärter, V., Dresen, S., Weinmann, W., Müller, M., Pütz, M., & Ferreirós, N. (2009) · Journal of Mass Spectrometry · doi:10.1002/jms.1558 · Cited by 660
Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens
Robbe, D., Kopf, M., Remaury, A., Bockaert, J., & Manzoni, O. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122149199 · Cited by 631
Cannabinoid Ligands Targeting TRP Channels
Muller, C., Morales, P., & Reggio, P. H. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00487 · Cited by 567
The endocannabinoid system in guarding against fear, anxiety and stress
Lutz, B., Marsicano, G., Maldonado, R., & Hillard, C. J. (2015) · Nature reviews. Neuroscience · doi:10.1038/nrn4036 · Cited by 506
Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
A cannabinoid mechanism in relapse to cocaine seeking
De Vries, T. J., Shaham, Y., Homberg, J. R., Crombag, H., Schuurman, K., Dieben, J., Vanderschuren, L. J. M. J., & Schoffelmeer, A. N. M. (2001) · Nature Medicine · doi:10.1038/nm1001-1151 · Cited by 432
High-resolution crystal structure of the human CB1 cannabinoid receptor
Shao, Z., Yin, J., Chapman, K., Grzemska, M., Clark, L., Wang, J., & Rosenbaum, D. M. (2016) · Nature · doi:10.1038/nature20613 · Cited by 419
Wise, R. A., & Robble, M. A. (2020) · Annual Review of Psychology · doi:10.1146/annurev-psych-010418-103337 · Cited by 404
Crystal Structure of the Human Cannabinoid Receptor CB2
Li, X., Hua, T., Vemuri, K., Ho, J.-H., Wu, Y., Wu, L., Popov, P., Benchama, O., Zvonok, N., Locke, K., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.011 · Cited by 400
Wagner, F. A. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.10.918 · Cited by 380
Dissecting the diversity of midbrain dopamine neurons
Roeper, J. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.03.003 · Cited by 373
Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors
Gessa, G., Melis, M., Muntoni, A., & Diana, M. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01442-8 · Cited by 370
Robbe, D., Alonso, G., Duchamp, F., Bockaert, J., & Manzoni, O. J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-01-00109.2001 · Cited by 366
Cannabinoids Enhance Subsecond Dopamine Release in the Nucleus Accumbens of Awake Rats
Cheer, J. F., Wassum, K. M., Heien, M. L. A. V., Phillips, P. E. M., & Wightman, R. M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-04.2004 · Cited by 343
Hurd, Y. L., Spriggs, S., Alishayev, J., Winkel, G., Gurgov, K., Kudrich, C., Oprescu, A. M., & Salsitz, E. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18101191 · Cited by 343
“Zombie” Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York
Adams, A. J., Banister, S. D., Irizarry, L., Trecki, J., Schwartz, M., & Gerona, R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1610300 · Cited by 320
Pregnenolone Can Protect the Brain from Cannabis Intoxication
Vallée, M., Vitiello, S., Bellocchio, L., Hébert-Chatelain, E., Monlezun, S., Martin-Garcia, E., Kasanetz, F., Baillie, G. L., Panin, F., Cathala, A., et al. (2014) · Science · doi:10.1126/science.1243985 · Cited by 319
Spicing things up: synthetic cannabinoids
Spaderna, M., Addy, P. H., & D’Souza, D. C. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3188-4 · Cited by 296
Withdrawal Phenomena and Dependence Syndrome After the Consumption of „Spice Gold“
Zimmermann, U. S., Winkelmann, P. R., Pilhatsch, M., Nees, J. A., Spanagel, R., & Schulz, K. (2009) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2009.0464 · Cited by 278
Self-citationSupply and demand for endocannabinoids
Alger, B. E., & Kim, J. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.03.003 · Cited by 268
Lupica, C. R., & Riegel, A. C. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.03.016 · Cited by 255
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review
Sarris, J., Sinclair, J., Karamacoska, D., Davidson, M., & Firth, J. (2020) · BMC Psychiatry · doi:10.1186/s12888-019-2409-8 · Cited by 253
Effects of Cannabinoids on Neurotransmission
Szabo, B., & Schlicker, E. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_11 · Cited by 252
mGluR5 Antagonist MPEP Reduces Ethanol-Seeking and Relapse Behavior
Bäckström, P., Bachteler, D., Koch, S., Hyytiä, P., & Spanagel, R. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300381 · Cited by 249
Self-citationFrench, E. D. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00278-4 · Cited by 236
Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis
Hindley, G., Beck, K., Borgan, F., Ginestet, C. E., McCutcheon, R., Kleinloog, D., Ganesh, S., Radhakrishnan, R., D'Souza, D. C., & Howes, O. D. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30074-2 · Cited by 227
Spanagel, R. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.3/rspanagel · Cited by 221
Self-citationHaney, M., Malcolm, R. J., Babalonis, S., Nuzzo, P. A., Cooper, Z. D., Bedi, G., Gray, K. M., McRae-Clark, A., Lofwall, M. R., Sparenborg, S., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.367 · Cited by 206
Metabotropic Glutamate Receptor Ligands as Potential Therapeutics for Addiction
Olive, M. (2009) · Current Drug Abuse Reviewse · doi:10.2174/1874473710902010083 · Cited by 200
Progress in brain cannabinoid CB2 receptor research: From genes to behavior
Jordan, C. J., & Xi, Z.-X. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.12.026 · Cited by 197
D'Souza, D. C., Cortes-Briones, J., Creatura, G., Bluez, G., Thurnauer, H., Deaso, E., Bielen, K., Surti, T., Radhakrishnan, R., Gupta, A., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30427-9 · Cited by 195
Heinz, A., Kiefer, F., Smolka, M. N., Endrass, T., Beste, C., Beck, A., Liu, S., Genauck, A., Romund, L., Banaschewski, T., et al. (2020) · Addiction Biology · doi:10.1111/adb.12866 · Cited by 176
Self-citationAcute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase
Kerbrat, A., Ferré, J.-C., Fillatre, P., Ronzière, T., Vannier, S., Carsin-Nicol, B., Lavoué, S., Vérin, M., Gauvrit, J.-Y., Le Tulzo, Y., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604221 · Cited by 171
Oleson, E. B., Beckert, M. V., Morra, J. T., Lansink, C. S., Cachope, R., Abdullah, R. A., Loriaux, A. L., Schetters, D., Pattij, T., Roitman, M. F., et al. (2012) · Neuron · doi:10.1016/j.neuron.2011.11.018 · Cited by 167
Cannabinoid receptors: nomenclature and pharmacological principles
Console-Bram, L., Marcu, J., & Abood, M. E. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.02.009 · Cited by 162
Cippitelli, A., Bilbao, A., Hansson, A. C., Del Arco, I., Sommer, W., Heilig, M., Massi, M., Bermúdez‐Silva, F. J., Navarro, M., Ciccocioppo, R., et al. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04056.x · Cited by 141
Role of the endocannabinoid system in drug addiction
Manzanares, J., Cabañero, D., Puente, N., García‐Gutiérrez, M. S., Grandes, P., & Maldonado, R. J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.013 · Cited by 128
The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder
Chye, Y., Christensen, E., Solowij, N., & Yücel, M. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00063 · Cited by 126
Soyka, M., Koller, G., Schmidt, P., Lesch, O.-M., Leweke, M., Fehr, C., Gann, H., & Mann, K. F. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318172b8bc · Cited by 126
Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse
da Cruz, J. F. O., Robin, L. M., Drago, F., Marsicano, G., & Metna‐Laurent, M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.002 · Cited by 124
Budney, A. J., Radonovich, K. J., Higgins, S. T., & Wong, C. J. (1998) · Experimental and Clinical Psychopharmacology · doi:10.1037//1064-1297.6.4.419 · Cited by 112
Nguyen, T., Thomas, B. F., & Zhang, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190708164841 · Cited by 110
The endocannabinoid system as a target for addiction treatment: Trials and tribulations
Sloan, M. E., Gowin, J. L., Ramchandani, V. A., Hurd, Y. L., & Foll, B. L. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.05.031 · Cited by 104
Kirsch, M., Gruber, I., Ruf, M., Kiefer, F., & Kirsch, P. (2016) · Addiction Biology · doi:10.1111/adb.12278 · Cited by 89
Role of mGluR5 neurotransmission in reinstated cocaine‐seeking
Wang, X., Moussawi, K., Knackstedt, L., Shen, H., & Kalivas, P. W. (2013) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00432.x · Cited by 83
Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review
Turna, J., Syan, S. K., Frey, B. N., Rush, B., Costello, M. J., Weiss, M., & MacKillop, J. (2019) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13964 · Cited by 83
Spencer, S., Neuhofer, D., Chioma, V. C., Garcia-Keller, C., Schwartz, D. J., Allen, N., Scofield, M. D., Ortiz-Ithier, T., & Kalivas, P. W. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.04.016 · Cited by 82
van den Brink, W., Addolorato, G., Aubin, H., Benyamina, A., Caputo, F., Dematteis, M., Gual, A., Lesch, O., Mann, K., Maremmani, I., et al. (2018) · Addiction Biology · doi:10.1111/adb.12645 · Cited by 75
Self-citationA Brain on Cannabinoids: The Role of Dopamine Release in Reward Seeking and Addiction
Peters, K. Z., Oleson, E. B., & Cheer, J. F. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a039305 · Cited by 71
Augier, E., Dulman, R. S., Damadzic, R., Pilling, A., Hamilton, J. P., & Heilig, M. A. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.53 · Cited by 64
Novak, M., Halbout, B., O'Connor, E. C., Rodriguez Parkitna, J., Su, T., Chai, M., Crombag, H. S., Bilbao, A., Spanagel, R., Stephens, D. N., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2550-10.2010 · Cited by 63
Self-citationDrug-Induced Alterations of Endocannabinoid-Mediated Plasticity in Brain Reward Regions
Zlebnik, N. E., & Cheer, J. F. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.1712-16.2016 · Cited by 60
Synthetic cannabinoids and their impact on neurodevelopmental processes
Alexandre, J., Carmo, H., Carvalho, F. D., & Silva, J. P. (2019) · Addiction Biology · doi:10.1111/adb.12824 · Cited by 55
Robinson, J. D., Cinciripini, P. M., Karam‐Hage, M., Aubin, H., Dale, L. C., NIAURA, R. S., Anthenelli, R. M., & the STRATUS Group (2017) · Addiction Biology · doi:10.1111/adb.12508 · Cited by 44
Wakeford, A. G. P., Wetzell, B. B., Pomfrey, R. L., Clasen, M. M., Taylor, W. W., Hempel, B. J., & Riley, A. L. (2017) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000135 · Cited by 41
Endocannabinoid LTD in Accumbal D1 Neurons Mediates Reward-Seeking Behavior
Bilbao, A., Neuhofer, D., Sepers, M. D., Wei, S., Eisenhardt, M., Hertle, S., Lassalle, O., Ramos, A., Puente, N., Lerner, R., et al. (2020) · iScience · doi:10.1016/j.isci.2020.100951 · Cited by 41
Self-citationPanlilio, L. V., & Justinová, Z. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.193 · Cited by 39
Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gαi/o protein inhibitor
Porcu, A., Melis, M., Tureček, R., Ullrich, C., Mocci, I., Bettler, B., Gessa, G. L., & Castelli, M. P. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.024 · Cited by 39
Approach bias modification for cannabis use disorder: A proof-of-principle study
Sherman, B. J., Baker, N. L., Squeglia, L. M., & McRae‐Clark, A. L. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2018.01.012 · Cited by 33
Sahlem, G. L., Caruso, M. A., Short, E. B., Fox, J. B., Sherman, B. J., Manett, A. J., Malcolm, R. J., George, M. S., & McRae‐Clark, A. L. (2019) · Brain stimulation · doi:10.1016/j.brs.2019.09.014 · Cited by 20
Cited by
Consequences of adolescent drug use
Steinfeld, M. R., & Torregrossa, M. M. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02590-4 · Cited by 237
Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review
Hasbi, A., Madras, B. K., & George, S. R. (2023) · Brain Sciences · doi:10.3390/brainsci13020325 · Cited by 79
“spiny neurons (D1-MSNs) (reviewed in [62]).”
BackgroundInfluentialThe Impact of Cannabidiol on Human Brain Function: A Systematic Review
Batalla, A., Bos, J., Postma, A., & Bossong, M. G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.618184 · Cited by 80
“…promising effects of CBD on reducing craving, negative affect and motivation for substance use (Chye et al., 2019; Hurd et al., 2019; Freeman et al., 2020; Spanagel, 2020), phenomena associated with fronto-striatal and limbic network disbalances (Koob and Volkow, 2016; Volkow and Boyle, 2018).”
BackgroundChronic Pain and Psychiatric Conditions
Johnston, K. J. A., & Huckins, L. M. (2022) · Complex Psychiatry · doi:10.1159/000527041 · Cited by 88
“The ECS also plays a role in nociceptive signaling and chronic pain [309–312], again involving dopamine transmission and reward circuitry in the brain [312, 313], in addition to being highlighted as a potential therapeutic target in ADHD [299, 314–316].”
BackgroundCannabidiol in the context of substance use disorder treatment: A systematic review
Paulus, V., Billieux, J., Benyamina, A., & Karila, L. (2022) · Addictive Behaviors · doi:10.1016/j.addbeh.2022.107360 · Cited by 58
Metadata
- Authors
- Spanagel, R.
- Affiliations
- Heidelberg University (DE)
- Corresponding author
- Spanagel, Rainer
- ORCID
- Spanagel, Rainer
- Venue
- Dialogues in Clinical Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2020-09-30
- Volume
- 22
- Issue
- 3
- Pages
- 241-250
- ISSN
- 1294-8322 (ISSN-L)
- 1958-5969
- PMC
- PMC7605022
- OpenAlex
- W3105701481
- Cited by
- 127
- References
- 72
- Citations by year
- 2026: 21 · 2025: 22 · 2024: 29 · 2023: 26 · 2022: 18 · 2021: 10 · 2020: 1
- FWCI
- 8.24
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Dialogues in Clinical Neuroscience (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- cannabinoids, endocannabinoid system, reward processing, addiction, cannabis use disorder, delta-9-tetrahydrocannabinol, synthetic cannabinoids, CB1 receptor, dopamine, ventral tegmental area, drug craving, relapse, corticostriatal pathway, fatty acid amide hydrolase inhibitors, allosteric modulators, cannabidiol, alcoholism, opioid use disorder
- MeSH terms
- Animals, Cannabinoids, Marijuana Abuse, Humans, Reward, Behavior, Addictive, Receptors, Cannabinoid, Drug-Seeking Behavior, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.